Jonathan Chang
Stock Analyst at Leerink Partners
(0.65)
# 3,898
Out of 4,935 analysts
88
Total ratings
31.08%
Success rate
-19.48%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jonathan Chang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| REPL Replimune Group | Downgrades: Market Perform | $21 → $3 | $5.48 | -45.26% | 10 | Jul 22, 2025 | |
| ZLAB Zai Lab | Maintains: Outperform | $73 → $75 | $34.08 | +120.07% | 9 | Jun 30, 2025 | |
| GMAB Genmab | Upgrades: Outperform | $27 | $22.69 | +19.00% | 10 | Feb 13, 2025 | |
| IMCR Immunocore Holdings | Initiates: Outperform | $74 | $31.93 | +131.76% | 1 | Apr 29, 2024 | |
| NBTX Nanobiotix | Initiates: Outperform | $11 | $7.19 | +52.99% | 1 | Dec 8, 2023 | |
| NVCR NovoCure | Initiates: Outperform | $51 | $11.51 | +343.09% | 1 | Aug 4, 2023 | |
| KPTI Karyopharm Therapeutics | Maintains: Market Perform | $90 → $75 | $3.97 | +1,789.17% | 12 | Jan 10, 2023 | |
| BCYC Bicycle Therapeutics | Maintains: Outperform | $48 → $50 | $7.46 | +570.24% | 4 | Aug 22, 2022 | |
| RVMD Revolution Medicines | Maintains: Outperform | $31 → $30 | $34.95 | -14.16% | 4 | Aug 10, 2022 | |
| MGNX MacroGenics | Maintains: Outperform | $15 → $12 | $1.61 | +645.34% | 8 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $325 → $350 | $6.61 | +5,195.01% | 5 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $25 → $26 | $6.32 | +311.39% | 5 | Jun 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $2 → $3 | $0.08 | +3,514.46% | 8 | May 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $41 → $28 | $5.96 | +369.80% | 3 | Feb 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $57 → $53 | $7.32 | +624.04% | 7 | Aug 5, 2021 |
Replimune Group
Jul 22, 2025
Downgrades: Market Perform
Price Target: $21 → $3
Current: $5.48
Upside: -45.26%
Zai Lab
Jun 30, 2025
Maintains: Outperform
Price Target: $73 → $75
Current: $34.08
Upside: +120.07%
Genmab
Feb 13, 2025
Upgrades: Outperform
Price Target: $27
Current: $22.69
Upside: +19.00%
Immunocore Holdings
Apr 29, 2024
Initiates: Outperform
Price Target: $74
Current: $31.93
Upside: +131.76%
Nanobiotix
Dec 8, 2023
Initiates: Outperform
Price Target: $11
Current: $7.19
Upside: +52.99%
NovoCure
Aug 4, 2023
Initiates: Outperform
Price Target: $51
Current: $11.51
Upside: +343.09%
Karyopharm Therapeutics
Jan 10, 2023
Maintains: Market Perform
Price Target: $90 → $75
Current: $3.97
Upside: +1,789.17%
Bicycle Therapeutics
Aug 22, 2022
Maintains: Outperform
Price Target: $48 → $50
Current: $7.46
Upside: +570.24%
Revolution Medicines
Aug 10, 2022
Maintains: Outperform
Price Target: $31 → $30
Current: $34.95
Upside: -14.16%
MacroGenics
Aug 9, 2022
Maintains: Outperform
Price Target: $15 → $12
Current: $1.61
Upside: +645.34%
Aug 9, 2022
Maintains: Outperform
Price Target: $325 → $350
Current: $6.61
Upside: +5,195.01%
Jun 3, 2022
Maintains: Outperform
Price Target: $25 → $26
Current: $6.32
Upside: +311.39%
May 9, 2022
Maintains: Market Perform
Price Target: $2 → $3
Current: $0.08
Upside: +3,514.46%
Feb 25, 2022
Maintains: Outperform
Price Target: $41 → $28
Current: $5.96
Upside: +369.80%
Aug 5, 2021
Maintains: Outperform
Price Target: $57 → $53
Current: $7.32
Upside: +624.04%